Pharmacokinetics of mirtazapine from orally administered tablets: Influence of a high-fat meal

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 22, Issue 2, 1997, Pages 103-110

  Cohen, M ^a   Panagides, J ^a   Timmer, C J ^b   Huisman, J A M ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NV ORGANON   (Netherlands)

Author keywords

Antidepressant; Mirtazapine; Org 3770; Pharmacokinetics; Remeron

Indexed keywords

MIRTAZAPINE; TETRACYCLIC ANTIDEPRESSANT AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FAT INTAKE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0030742298     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03189792     Document Type: Article

References (26)

1. De Boer T., Nefkens F., Van Helvoirt A. (1994) : The α2 antagonist Org 3770 enhances serotonin transmission in vivo. Eur. J. Pharmacol., 253, R5-R6.
2. 1A-mediated serotonergic neurotransmission. CNS Drugs, 4 (Suppl 1), 29-38.
3. De Montigny C., Haddjeri N., Mongeau R., Blier, P. (1995) : The effects of mirtazapine on interactions between central noradrenergic and serotonergic systems. CNS Drugs, 4 (Suppl 1), 13-17.
4. De Boer T., Maura G., Raiteri M., De Vos C.J., Wieringa J., Pinder R.M. (1988) : Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology, 27, 399-408.
5. Bremner J.D. (1995) : A double-blind comparison of Org 3770, amitriptyline and placebo in major depression. J. Clin. Psychiatry, 56, 519-525.
6. Claghorn J.L., Lessem, M.D. (1995) : A double-blind placebo controlled study of Org 3770 in depressed outpatients. J. Affect. Disord., 34, 165-171.
7. Sitsen J.M.A., Zivkov M., Dieterle D. (1995) : Wirksamkeit und Verträglichkeit von Org 3770 bei Patienten mit einer Major Depression. Psychopharmakotherapie, 2, 68-71.
8. Kahn M.C. (1995) : A randomised, double-blind, placebo-controlled, 5-weeks' study of Org 3770 (mirtazapine) in major depression. Hum. Psychopharmacol., 10, (Suppl 2), S119-S124.
9. Van Moffaert M., De Wilde J., Vereecken A. et al. (1995) : Mirtazapine is more effective than trazodone. A controlled study in hospitalised patients with major depression. Int. Clin. Psychopharmacol., 10, 3-9.
10. Mullin J., Lodge A., Bennie E., McCreadie R., Bhatt G.S., Fenton G. (1997) : A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J. Psychopharmacol., In press.
11. Zivkov M., De Jongh G. (1995) : Org 3770 vs amitriptyline; a 6-week, randomised double-blind multicentre trial in hospitalised patients. Hum. Psychopharmacol., 10, 263-271.
12. Richou H., Ruimy P., Charbaut J. et al. (1995) : A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770. Hum. Psychopharmacol., 10, 263-271.
13. Marttilla M., Jääskeläinen J., Järvi R. et al. (1995) : A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur. Neuropsychopharmacol., 5, 441-446.
14. Zivkov M., Roes K.C.B., Pols A.G. (1995) : Efficacy of Org 3770 (mirtazapine) vs amitriptyline in patients with major depressive disorder: a meta-analysis. Hum. Psychopharmacol., 10 (Suppl 2), S135-S145.
15. Halikas J.A. (1995) : Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum. Psychopharmacol., 10 (Suppl 2), S125-S133.
16. Hoyberg O.J., Maragakis B., Mullin J. et al. (1997). A double blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr. Scand., In press.
17. Voortman G., Paanakker J.E. (1995) : Bioavailability of mirtazapine from Remeron® tablets after single and multiple oral dosing. Hum. Psychopharmacol., 10, (Suppl 2), S83-S96.
18. Timmer C.J., Lohmann A., Mink C.P.A. (1995) : Pharmacokinetic dose-proportionality study at steady state of mirtazapine from Remeron® tablets. Hum. Psychopharmacol., 10, (Suppl 2), S97-S106.
19. Timmer C.J., Paanakker J.E., Van Hal H.J.M. (1996) : Pharmacokinetics of mirtazapine from orally administered tablets; influence of gender, age and treatment regimen. Hum. Psychopharmacol., In press.
20. 14C. J. Labelled Compounds Radiopharmaceut., 27, 1055-1068.
21. Paanakker J.E., Van Hal H.J.M. (1987) : Capillary gas chromatographic assay for the routine monitoring of the antidepressant mepirzepine in human plasma. J. Chromatogr. Biomed. Appl., 417, 203-207.
22. SAS Institute Inc. (1989) : SAS User's Guide, Version 6.06. Cary, NC, USA: SAS Institute Inc.
23. US Food and Drug Administration Guidance (1992) : Statistical procedures for bioequivalence testing using a standard two-treatment cross-over design. Statement prepared by the Division of Bioequivalence, Office of Generic Drugs of the FDA, informal communication under 21 CFR 10.90.
24. Commission on the European Communities, Committee for Proprietary Medicinal Products CPMP. Note for Guidance, Investigation of Bioavailability and Bioequivalence, III/54/89-EN.
25. Wijnand H.P. (1993) : Bioequivalence revisited -non-parametric analysis of two-period cross-over studies. Computer Methods Progr. Biomed., 49, 249-259.
26. Schuirmann D.J. (1987) : A comparison of the two one-sided tests procedure and the power approach for testing equivalence in bioequivalence assessment. J. Pharmacokinet. Biopharm., 15, 657-680.